Human OX40 Ligand / TNFSF4 Protein, Mouse IgG2a Fc Tag, low endotoxin

用户评价
货号-规格
价格
Qty.
OXL-H5250-100ug
¥3675.00
OXL-H5250-1mg (500ug X 2)
¥24255.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    OX40L, TNFSF4, CD252, Glycoprotein Gp34, TXGP1, CD134 ligand, CD134L

  • 表达区间及表达系统(Source)

    Human OX40 Ligand Protein, Mouse IgG2a Fc Tag (OXL-H5250) is expressed from human 293 cells (HEK293). It contains AA Gln 51 - Leu 183 (Accession # P23510-1).

    Predicted N-terminus: Gln 51

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    OX40 Ligand Structure

    This protein carries a mouse IgG2a Fc tag at the C-terminus.

    The protein has a calculated MW of 42.3 kDa. The protein migrates as 53-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 内毒素(Endotoxin)

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • 纯度(Purity)

    >95% as determined by SDS-PAGE.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

  • 电泳(SDS-PAGE)

    OX40 Ligand SDS-PAGE

    Human OX40 Ligand Protein, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • 活性(Bioactivity)-ELISA

     OX40 Ligand ELISA

    Immobilized Human OX40, Fc Tag (Cat. No. OX0-H5255) at 0.5 μg/mL (100 μL/well) can bind Human OX40 Ligand Protein, Mouse IgG2a Fc Tag (Cat. No. OXL-H5250) with a linear range of 0.8-13 ng/mL (QC tested).

    Protocol
  • 活性(Bioactivity)-BLI

     OX40 Ligand BLI

    Loaded Human OX40 Ligand Protein, Mouse IgG2a Fc Tag (Cat. No. OXL-H5250) on Protein A Biosensor, can bind Human OX40, His Tag (Cat. No. OX0-H5224) with an affinity constant of 2 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  • 活性(Bioactivity)-FACS

     OX40 Ligand FACS

    FACS assay shows that recombinant Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) can bind to 293T cell overexpressing human OX40. The concentration of OX40 Ligand is 0.003 μg/ml (Routinely tested).

    Protocol
  •  OX40 Ligand FACS

    FACS analysis shows that the binding of Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) to 293T overexpressing OX40 was inhibited by increasing concentration of neutralizing anti-OX40 antibody. The concentration of OX40 Ligand used is 0.002 μg/ml. IC50=3.021 μg/ml (Routinely tested).

    Protocol

用户评价
发表评论

背景介绍

Tumor necrosis factor ligand superfamily member 4 (TNFSF4) is also known as glycoprotein Gp34, OX40 ligand (OX40L), TAX transcriptionally-activated glycoprotein 1 and CD252, which belongs to the tumor necrosis factor family. TNFSF4 is the ligand for CD134 and is expressed on such cells as DC2s (a subtype of dendritic cells) enabling amplification of Th2 cell differentiation. The interaction of TNFSF4-TNFSF4 is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. Furthermore, similar to other TNF superfamily members, membrane-bound OX40 Ligand (TNFSF4) exists as a homotrimer. Human TNFSF4 shares 46% amino acid sequence identity with its mouse counterpart.

前沿进展

 
药物研发进展
  • 英文全称:

    Tumor necrosis factor ligand superfamily member 4

  • 中文全称:

    OX40配体

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    8 详情

  • 最高研发阶段:

    临床三期

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 背景介绍